11 patents
Utility
Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose
11 Jan 24
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose.
Dalia Megiddo
Filed: 5 Apr 23
Utility
Pharmacokinetics of Nmda Receptor Antagonists
12 Oct 23
The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Raj Mehra, Timothy Whitaker
Filed: 11 Apr 23
Utility
Reduced Sedation and Dissociation In Treating Neurological Disorders
31 Aug 23
The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Raj Mehra, Timothy Whitaker
Filed: 11 Apr 23
Utility
Methods of Treating Suicidality
3 Aug 23
The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Raj Mehra, Timothy Whitaker
Filed: 11 Apr 23
Utility
Reducing Side Effects of Nmda Antagonists
2 Mar 23
The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Raj Mehra, Timothy Whitaker
Filed: 22 Jan 21
Utility
Trehalose Formulations and Uses Thereof
8 Dec 22
The present disclosure relates to methods of treating or alleviating one or more symptoms of mucopolysaccharidoses in a subject, via administering a trehalose formulation to the subject.
Raj Mehra, Warren Wasiewski, Gopal Krishna
Filed: 29 Sep 20
Utility
Compositions and Methods for Treating an Aggregation Disease or Disorder
15 Sep 22
The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.
Dalia Megiddo
Filed: 31 Jan 22
Utility
Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose
21 Apr 22
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose.
Dalia Megiddo
Filed: 23 Jun 21
Utility
Compositions and Methods for Treating an Aggregation Disease or Disorder
14 Jan 21
The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.
Dalia Megiddo
Filed: 15 Jul 20
Utility
Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose
11 Dec 19
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose.
Dalia Megiddo
Filed: 1 Jul 19
Utility
Compositions and Methods for Treating an Aggregation Disease or Disorder
6 Nov 19
The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.
Dalia MEGIDDO
Filed: 30 Jan 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first